Skip to main content
Signal8
Launch Terminal

Alaunos Therapeutics, Inc. (TCRT)

Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc.

NASDAQ:TCRTHealthcare
+3.17%$1.95
AH$1.86-4.62%vs close
Mkt Cap$7.22M
Float2.68M
O/S3.7M
Vol
$ Vol
RVOL
Inst Own2.4%
SI30.5%
Earnings
Dilution
Alaunos Therapeutics, Inc. logoNASDAQ:TCRT$1.95+3.17%
Phase Distribution
37 lead-sponsored trials·0 active·22 completed
Phase 121
Phase 1/26
Phase 26
Phase 32
Not applicable2
(7 more as collaborator)
Status Overview
Completed22
Stopped15

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Terminated

    Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

    Palifosfamide-Tris, doxorubicin

    Soft Tissue Sarcoma

    Enrollment
    447
    Start
    Aug 2010
    Primary Completion
    Mar 2013
    Completion
    Mar 2013
    NCT01168791
  • Phase 3
    Terminated

    Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)

    Carboplatin, Palifosfamide-tris

    Extensive-Stage Small Cell Lung Cancer

    Enrollment
    188
    Start
    Jun 2012
    Primary Completion
    Dec 2014
    Completion
    Dec 2014
    NCT01555710
  • Phase 2
    Terminated

    Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

    Darinaparsin

    Hematologic Neoplasms, Bone Marrow Neoplasms +1

    Enrollment
    50
    Start
    Dec 2006
    Primary Completion
    Jun 2009
    Completion
    Jun 2009
    NCT00421213
  • Phase 2
    Terminated

    A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

    Darinaparsin

    Hepatocellular Carcinoma

    Enrollment
    15
    Start
    May 2007
    Primary Completion
    Aug 2008
    Completion
    Aug 2008
    NCT00423306
  • Phase 2
    Completed

    A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

    Darinaparson

    Multiple Myeloma

    Enrollment
    17
    Start
    Jan 2007
    Primary Completion
    Dec 2007
    Completion
    Dec 2008
    NCT00423644
  • Phase 2
    Terminated

    A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma

    Palifosfamide-Tris, Doxorubicin

    Soft Tissue Sarcoma

    Enrollment
    67
    Start
    Sep 2008
    Primary Completion
    Sep 2010
    Completion
    Sep 2010
    NCT00718484
  • Phase 2
    Terminated

    Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.

    Palifosfamide

    Breast Cancer Nos Metastatic Recurrent

    Enrollment
    12
    Start
    Apr 2013
    Primary Completion
    Aug 2014
    Completion
    Aug 2014
    NCT01703754
  • Phase 2
    Terminated

    Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

    Ad-RTS-hIL-12, Veledimex

    Glioblastoma

    Enrollment
    40
    Start
    Aug 2019
    Primary Completion
    Aug 2021
    Completion
    Aug 2021
    NCT04006119
  • Phase 1/2
    Completed

    Study of ZIO-101 in Multiple Myeloma

    ZIO-101 (Darinaparsin)

    Multiple Myeloma

    Enrollment
    35
    Start
    Jan 2006
    Primary Completion
    Aug 2007
    Completion
    Aug 2007
    NCT00303199
  • Phase 1/2
    Completed

    Study of ZIO-201 in Advanced Sarcoma

    ZIO-201

    Advanced Sarcoma

    Enrollment
    54
    Start
    Feb 2006
    Primary Completion
    Jan 2008
    Completion
    Jan 2008
    NCT00439686
  • Phase 1/2
    Completed

    Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

    INXN-2001, INXN-1001

    Melanoma

    Enrollment
    26
    Start
    Aug 2011
    Primary Completion
    Sep 2014
    Completion
    Sep 2014
    NCT01397708
  • Phase 1/2
    Terminated

    A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer

    Ad-RTS-hIL-12, Veledimex

    Metastatic Breast Cancer

    Enrollment
    9
    Start
    Jul 2015
    Primary Completion
    Jul 2016
    Completion
    Jul 2016
    NCT02423902
  • Phase 1/2
    Terminated

    A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

    Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor)

    Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma

    Enrollment
    6
    Start
    Sep 2017
    Primary Completion
    Sep 2021
    Completion
    Sep 2021
    NCT03330197
  • Phase 1/2
    Terminated

    Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

    Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)

    Gynecologic Cancer, Colorectal Cancer +10

    Enrollment
    8
    Start
    Apr 2022
    Primary Completion
    Aug 2023
    Completion
    Aug 2023
    NCT05194735
  • Phase 1
    Completed

    A Protocol for the Safety and Tolerance of Intravenous Isophosphoramide Mustard (IPM) in Patients With Advanced Cancer

    ZIO-201

    Advanced Cancer

    Enrollment
    30
    Start
    Feb 2006
    Primary Completion
    Oct 2007
    Completion
    Oct 2007
    NCT00421135
  • Phase 1
    Completed

    Phase I Study of Indibulin in Patients With Solid Tumors

    indibulin

    Solid Tumors

    Enrollment
    47
    Start
    Apr 2003
    Primary Completion
    Sep 2008
    Completion
    Sep 2008
    NCT00591136
  • Phase 1
    Completed

    Phase I Study in Advanced Solid Tumors

    indibulin

    Solid Tumors

    Enrollment
    22
    Start
    Jul 2007
    Primary Completion
    Feb 2009
    Completion
    Mar 2009
    NCT00591292
  • Phase 1
    Completed

    Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

    indibulin, erlotinib

    Advanced Solid Tumors

    Enrollment
    10
    Start
    Jan 2008
    Primary Completion
    Dec 2008
    Completion
    Dec 2009
    NCT00591383
  • Phase 1
    Completed

    A Phase I Trial of ZIO-101 in Solid Tumors

    ZIO-101 (Darinaparsin)

    Solid Tumors

    Enrollment
    40
    Start
    Jul 2005
    Primary Completion
    Jul 2008
    Completion
    Jul 2008
    NCT00591396
  • Phase 1
    Completed

    Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

    ZIO-101-C (Darinaparsin)

    Advanced Cancer

    Enrollment
    23
    Start
    Aug 2007
    Primary Completion
    Mar 2010
    Completion
    Mar 2011
    NCT00591422
  • Phase 1
    Completed

    Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans

    indibulin

    Advanced Cancer

    Enrollment
    20
    Start
    Oct 2007
    Primary Completion
    Jun 2008
    Completion
    Mar 2009
    NCT00591890
  • Phase 1
    Completed

    A Phase I Trial of ZIO-101 in Hematologic Cancers

    ZIO-101 (Darinaparsin)

    Acute Leukemia, Chronic Myeloproliferative Disease +4

    Enrollment
    12
    Start
    May 2005
    Primary Completion
    Jun 2008
    Completion
    Jun 2008
    NCT00592046
  • Phase 1
    Completed

    Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

    ZIO-101-C (Darinaparsin)

    Advanced Solid Tumors, Lymphomas

    Enrollment
    20
    Start
    Dec 2007
    Primary Completion
    Jan 2009
    Completion
    Jan 2010
    NCT00592163
  • Phase 1
    Withdrawn

    Study of Oral Palifosfamide Tris in Solid Tumors

    oral palifosfamide tris

    Advanced Cancer

    Enrollment
    0
    Start
    Mar 2008
    Primary Completion
    Nov 2009est.
    Completion
    Nov 2009est.
    NCT00607711
  • Phase 1
    Completed

    Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors

    ZIO-201-T and doxorubicin

    Advanced Cancer

    Enrollment
    30
    Start
    Jan 2008
    Primary Completion
    Jan 2009
    Completion
    Jan 2009
    NCT00608803

1-25 of 37

Search ClinicalTrials.gov for “Alaunos Therapeutics”